IL4 and renal cell adenocarcinoma: For example, studies by others have shown that sunitinib treatment for patients with renal cell cancer was associated with an increase in frequency of T cells producing IFN-γ (i.e., Th1 cells) and a decrease in T cells producing IL-4 (i.e., Th2 cells), which reverses the unfavorable Th1/Th2 ratio characteristic in this disease state.